Wilmington Savings Fund Society FSB Makes New $652,000 Investment in argenx SE (NASDAQ:ARGX)

Wilmington Savings Fund Society FSB purchased a new stake in shares of argenx SE (NASDAQ:ARGX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,202 shares of the company’s stock, valued at approximately $652,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ARGX. FMR LLC lifted its holdings in argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of argenx by 0.4% in the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after purchasing an additional 10,975 shares during the period. Clearbridge Investments LLC boosted its holdings in argenx by 3.6% in the 2nd quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock worth $265,535,000 after buying an additional 21,189 shares during the period. Wellington Management Group LLP boosted its holdings in argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after buying an additional 55,617 shares during the period. Finally, Sei Investments Co. raised its holdings in argenx by 15.2% during the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after acquiring an additional 50,477 shares during the period. Institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Baird R W downgraded argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their price objective for the company from $439.00 to $715.00 in a research report on Tuesday, November 5th. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 target price (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $617.00 target price on shares of argenx in a research note on Wednesday, November 20th. Finally, Guggenheim boosted their price target on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, argenx currently has an average rating of “Moderate Buy” and a consensus target price of $635.11.

argenx Stock Up 0.6 %

argenx stock opened at $607.21 on Monday. argenx SE has a 52-week low of $327.73 and a 52-week high of $630.00. The firm’s fifty day moving average is $581.03 and its 200 day moving average is $515.48. The company has a market cap of $36.66 billion, a price-to-earnings ratio of -690.01 and a beta of 0.59.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter last year, the firm earned ($1.25) EPS. On average, equities research analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.